{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:47:13Z","timestamp":1785926833891,"version":"3.56.0"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The landscape of immunotherapy in oncology has markedly advanced with the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, fundamentally reshaping cancer treatment by potentiating anti-tumor immune responses. PD-1\/PD-L1 blockade agents, such as FDA-approved nivolumab, pembrolizumab, and dostarlimab, have demonstrated significant clinical efficacy across various malignancies. Additionally, investigational agents like envafolimab, a novel PD-L1 inhibitor, are currently under clinical evaluation for efficacy and safety in solid tumors. This review examines the emerging data on envafolimab and discusses strategies to optimize its therapeutic impact, including combination regimens and personalized approaches. Tailoring treatments based on individual genetic, immunological, and microbiome profiles holds the potential to enhance response rates and the durability of outcomes. The integration of these factors is pivotal in advancing the precision and success of immunotherapy in oncology.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1918429","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:14:11Z","timestamp":1785924851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Envafolimab \u2013 novel anti-PD-1\/PD-L1 antibody in cancer treatment"],"prefix":"10.3389","volume":"17","author":[{"given":"Mateusz","family":"Kciuk","sequence":"first","affiliation":[{"name":"Department of Molecular Biotechnology and Genetics, University of Lodz","place":["Lodz, Poland"]},{"name":"Department of Functional Genomics, Faculty of Medicine, Medical University of Lodz","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Ko\u0142at","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Genetics, University of Lodz","place":["Lodz, Poland"]},{"name":"Department of Functional Genomics, Faculty of Medicine, Medical University of Lodz","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wanke","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Genetics, University of Lodz","place":["Lodz, Poland"]},{"name":"Doctoral School of Exact and Natural Sciences, University of Lodz","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Kontek","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Genetics, University of Lodz","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03013-3","article-title":"Chemotherapy: a double-edged sword in cancer treatment","volume":"71","author":"Behranvand","year":"2022","journal-title":"Cancer Immunol Immunother CII"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-3-031-27156-4_3","article-title":"Chemotherapy","volume":"185","author":"Hossain","year":"2023","journal-title":"Cancer Treat Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: Current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","article-title":"Regorafenib","volume":"211","author":"Ettrich","year":"2018","journal-title":"Recent Results Cancer Res Fortschr Krebsforsch Progres Dans Rech Sur Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.007","article-title":"The journey from discoveries in fundamental immunology to cancer immunotherapy","volume":"27","author":"Miller","year":"2015","journal-title":"Cancer Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102721","article-title":"Recent advances in molecular mechanisms of cancer immunotherapy","volume":"15","author":"Kciuk","year":"2023","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70296","article-title":"Immunotherapy in cancer: novel approaches and future perspectives","volume":"183","author":"Stefanska","year":"2026","journal-title":"Br J Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/op.22.00762","article-title":"Neoadjuvant immune checkpoint inhibitor therapy for patients with microsatellite instability-high colorectal cancer: Shedding light on the future","volume":"19","author":"Sahin","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104047","article-title":"Jemperli (Dostarlimab-gxly): An unprecedented cancer trial","volume":"79","author":"Ali","year":"2022","journal-title":"Ann Med Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2217\/imt-2022-0239","article-title":"The use of dostarlimab, a safe and efficient monotherapy in MSI-H rectal cancer patients, an alternative to surgery","volume":"15","author":"Baz","year":"2023","journal-title":"Immunotherapy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2178220","article-title":"Dostarlimab: From preclinical investigation to drug approval and future directions","volume":"19","author":"Cicala","year":"2023","journal-title":"Hum Vaccines Immunother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/b978-0-12-800267-4.00003-1","article-title":"Recognition of tumors by the innate immune system and natural killer cells","volume":"122","author":"Marcus","year":"2014","journal-title":"Adv Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: Present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf4726","article-title":"Architects of immunity: How dendritic cells shape CD8+ T cell fate in cancer","volume":"10","author":"Bhandarkar","year":"2025","journal-title":"Sci Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13668","article-title":"Faster cytotoxicity with age: Increased perforin and granzyme levels in cytotoxic CD8+ T cells boost cancer cell elimination","volume":"21","author":"Z\u00f6phel","year":"2022","journal-title":"Aging Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1186\/s12885-024-12605-y","article-title":"Association of CD8+TILs co-expressing granzyme A and interferon-\u03b3 with colon cancer cells in the tumor microenvironment","volume":"24","author":"Yang","year":"2024","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867098","article-title":"Escaping death: How cancer cells and infected cells resist cell-mediated cytotoxicity","volume":"13","author":"Tuomela","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315384","article-title":"Programmed cell death-ligand 1 in head and neck squamous cell carcinoma: Molecular insights, preclinical and clinical data, and therapies","volume":"23","author":"Meliante","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802769","article-title":"Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade","volume":"182","author":"Reynoso","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040530","article-title":"PD-1\/PD-L1 and DNA damage response in cancer","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114646","article-title":"The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy","volume":"162","author":"Mortezaee","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1186\/s12885-021-09009-7","article-title":"The effect of hypoxia on PD-L1 expression in bladder cancer","volume":"21","author":"Smith","year":"2021","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ijc.30077","article-title":"PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma","volume":"139","author":"Ruf","year":"2016","journal-title":"Int J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115622","article-title":"Microenvironmental regulation in tumor progression: Interactions between cancer-associated fibroblasts and immune cells","volume":"167","author":"Gao","year":"2023","journal-title":"BioMed Pharmacother Biomedecine Pharmacother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1113378","article-title":"CAFs orchestrates tumor immune microenvironment-a new target in cancer therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41420-024-01958-9","article-title":"Crosstalk between cancer-associated fibroblasts and regulated cell death in tumors: insights into apoptosis, autophagy, ferroptosis, and pyroptosis","volume":"10","author":"Chen","year":"2024","journal-title":"Cell Death Discov"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28045","article-title":"Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver","volume":"12","author":"Dom\u00e8nech","year":"2021","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/biology10050385","article-title":"Associations between DNA damage and PD-L1 expression in ovarian cancer, a potential biomarker for clinical response","volume":"10","author":"Mann","year":"2021","journal-title":"Biology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3694","article-title":"The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac167","article-title":"EGFR mutations and PD-L1 expression in early-stage non-small cell lung cancer: A real-world data from a single center in Brazil","volume":"27","author":"Alves Pinto","year":"2022","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-88","article-title":"The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients","volume":"11","author":"Yang","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00934-6","article-title":"Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti-PD-1\/PD-L1 therapy","volume":"18","author":"Veccia","year":"2023","journal-title":"Target Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031119","article-title":"Epigenetic modification of PD-1\/PD-L1-mediated cancer immunotherapy against melanoma","volume":"23","author":"Nanamori","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-022-00356-0","article-title":"New insights into epigenetic regulation of resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities","volume":"11","author":"Dai","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3892\/ijo.2022.5424","article-title":"Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)","volume":"61","author":"Ma","year":"2022","journal-title":"Int J Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u201cT cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf Open Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+T cells in the tumor immune microenvironment: New pathways to therapy","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750542","article-title":"Regulatory T cells: Regulation of identity and function","volume":"12","author":"Grover","year":"2021","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.14712\/18059694.2016.63","article-title":"Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders","volume":"53","author":"Kond\u011blkov\u00e1","year":"2010","journal-title":"Acta Med (Hradec Kralove)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108469","article-title":"Immunotherapy of cancer by targeting regulatory T cells","volume":"104","author":"Chen","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.06.008","article-title":"Therapeutic targeting of regulatory T cells in cancer","volume":"8","author":"Shan","year":"2022","journal-title":"Trends Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"14114","DOI":"10.3390\/ijms241814114","article-title":"The role of regulatory T cells in cancer treatment resistance","volume":"24","author":"D\u0105browska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666181112114958","article-title":"Small molecules as PD-1\/PD-L1 pathway modulators for cancer immunotherapy","volume":"24","author":"Jiao","year":"2018","journal-title":"Curr Pharm Des"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.31083\/fbl26995","article-title":"Tumor-associated macrophages in immunotherapy","volume":"288","author":"Yan","year":"2021","journal-title":"FEBS J"},{"key":"B58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13046-022-02272-x","article-title":"Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies","volume":"41","author":"Kumari","year":"2022","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/imt-2016-0135","article-title":"Tumor-associated macrophages: implications in cancer immunotherapy","volume":"9","author":"Petty","year":"2017","journal-title":"Immunotherapy"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888713","article-title":"Shaping polarization of tumor-associated macrophages in cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13578-022-00823-5","article-title":"Targeting tumor-associated macrophages for cancer treatment","volume":"12","author":"Li","year":"2022","journal-title":"Cell Biosci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113285","article-title":"The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy","volume":"12","author":"Quatrini","year":"2020","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886931","article-title":"Burgeoning exploration of the role of natural killer cells in anti-PD-1\/PD-L1 therapy","volume":"13","author":"Bai","year":"2022","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113356","article-title":"If small molecules immunotherapy comes, can the prime be far behind","volume":"218","author":"Zhang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/imr.13381","article-title":"Single domain antibody: development and application in biotechnology and biopharma","volume":"328","author":"Yu","year":"2024","journal-title":"Immunol Rev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01671-w","article-title":"Envafolimab: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01095-1","article-title":"Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors","volume":"14","author":"Li","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/celldisc.2017.4","article-title":"Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade","volume":"3","author":"Zhang","year":"2017","journal-title":"Cell Discov"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2125799","article-title":"Envafolimab - first PD-1\/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors","volume":"22","author":"Chen","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.5c24260","article-title":"PD-L1 blockade with biodegradable envafolimab-loaded microspheres synergizes with transarterial chemoembolization to overcome myeloid-derived suppressor cell-driven immune escape in hepatocellular carcinoma","volume":"18","author":"Liu","year":"2026","journal-title":"ACS Appl Mater Interfaces"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.104026","article-title":"Subcutaneously administered anti-PD-(L)1 antibodies are predominantly absorbed via the lymphatic system, resulting in high drug exposure to draining lymph nodes","volume":"115","author":"Fei","year":"2026","journal-title":"J Pharm Sci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3892\/ol.2023.13937","article-title":"Efficacy and safety of envafolimab in the treatment of advanced dMMR\/MSI-H solid tumors: a single-arm meta-analysis","volume":"26","author":"Fan","year":"2023","journal-title":"Oncol Lett"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13817","article-title":"First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors","volume":"26","author":"Papadopoulos","year":"2021","journal-title":"Oncologist"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01287-7","article-title":"Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors","volume":"40","author":"Shimizu","year":"2022","journal-title":"Invest New Drugs"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70101","article-title":"Safety and efficacy of the first subcutaneous ICI, envafolimab, in the treatment of advanced lung cancer patients: a real-world study","volume":"16","author":"Dou","year":"2025","journal-title":"Thorac Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae102","article-title":"Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors","volume":"29","author":"Cui","year":"2024","journal-title":"Oncologist"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bulcan.2016.11.006","article-title":"Immunotherapy and patients treated for cancer with microsatellite instability","volume":"104","author":"Colle","year":"2017","journal-title":"Bull Cancer (Paris)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_200821","article-title":"Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management","volume":"38","author":"Overman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"B81","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1680636","article-title":"Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab","volume":"19","author":"J\u00e1come","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041022","article-title":"Challenges and therapeutic opportunities in the dMMR\/MSI-H colorectal cancer landscape","volume":"15","author":"Mulet-Margalef","year":"2023","journal-title":"Cancers"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000152","article-title":"Endometrial cancer: molecular classification and future treatments","volume":"1","author":"Corr","year":"2022","journal-title":"BMJ Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.12.031","article-title":"High homogeneity of MMR deficiency in ovarian cancer","volume":"156","author":"Fraune","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158726","article-title":"Microsatellite instability: from the implementation of the detection to a prognostic and predictive role in cancers","volume":"23","author":"Amato","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B91","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2017-ng01","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092249","article-title":"Homologous recombination repair deficiency and implications for tumor immunogenicity","volume":"13","author":"van Wilpe","year":"2021","journal-title":"Cancers"},{"key":"B95","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ctrv.2011.04.015","article-title":"Defective homologous recombination in human cancers","volume":"38","author":"Cerbinskaite","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0863-0","article-title":"Hypermutated tumors and immune checkpoint inhibition","volume":"78","author":"Ciombor","year":"2018","journal-title":"Drugs"},{"key":"B97","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11523-024-01077-6","article-title":"Efficacy and safety of neoadjuvant subcutaneous envafolimab in dMMR\/MSI-H locally advanced colon cancer","volume":"19","author":"Li","year":"2024","journal-title":"Target Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01077-6","article-title":"Correction to: efficacy and safety of neoadjuvant subcutaneous envafolimab in dMMR\/MSI-H locally advanced colon cancer","volume":"19","author":"Li","year":"2024","journal-title":"Target Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70203","article-title":"Efficacy and safety of PD-L1 blockade envafolimab as neoadjuvant treatment in mismatch repair-deficient, locally advanced colorectal cancer: an open-label, single-arm study","volume":"131","author":"Fang","year":"2025","journal-title":"Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001960","article-title":"Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg Lond Engl"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1619043","article-title":"Immune activation following PD-L1 inhibitor plus chemoradiotherapy in locally advanced rectal cancer: a retrospective, single-arm study","volume":"16","author":"Fan","year":"2025","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s12916-025-04385-4","article-title":"Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial","volume":"23","author":"Zhao","year":"2025","journal-title":"BMC Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10637-024-01468-6","article-title":"Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study","volume":"43","author":"Jiang","year":"2025","journal-title":"Invest New Drugs"},{"key":"B104","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-025-01506-x","article-title":"Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage","volume":"43","author":"Ma","year":"2025","journal-title":"Invest New Drugs"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1505195","article-title":"Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00384-025-04806-z","article-title":"The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study","volume":"40","author":"Liu","year":"2025","journal-title":"Int J Colorectal Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1116805","article-title":"Epigenetic reprogramming in cancer: From diagnosis to treatment","volume":"11","author":"da S. Costa","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020211","article-title":"Epigenetic drugs and their immune modulating potential in cancers","volume":"10","author":"Liang","year":"2022","journal-title":"Biomedicines"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S217767","article-title":"DNA methyltransferase inhibitors: Catalysts for antitumour immune responses","volume":"12","author":"Dan","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010169","article-title":"Targeting epigenetic mechanisms: A boon for cancer immunotherapy","volume":"11","author":"Parab","year":"2023","journal-title":"Biomedicines"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.06.002","article-title":"The contribution of epigenetics to cancer immunotherapy","volume":"41","author":"Villanueva","year":"2020","journal-title":"Trends Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.809761","article-title":"A new trend in cancer treatment: The combination of epigenetics and immunotherapy","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.04.012","article-title":"Epigenetics and immunotherapy: The current state of play","volume":"87","author":"Dunn","year":"2017","journal-title":"Mol Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030365","article-title":"Epigenetic perspective of immunotherapy for cancers","volume":"12","author":"Keshari","year":"2023","journal-title":"Cells"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7175","article-title":"Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12865-024-00651-x","article-title":"\u03b2-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer","volume":"25","author":"Geng","year":"2024","journal-title":"BMC Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1502945","article-title":"Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: findings from a single-center retrospective study","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf210","article-title":"Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposide","volume":"30","author":"Ding","year":"2025","journal-title":"Oncologist"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71756","article-title":"Efficacy and safety of envafolimab combined with capecitabine and lenvatinib as postoperative adjuvant therapy in resected biliary tract cancer with high-risk recurrence factors: a phase II single-center prospective study","volume":"15","author":"Tian","year":"2026","journal-title":"Cancer Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096314855240619181909","article-title":"Envafolimab inhibits the growth of gastric cancer cells with low PD-L1 expression through the DDX20\/NF-\u03baB\/TNF-\u03b1 signaling pathway","volume":"25","author":"Dong","year":"2025","journal-title":"Curr Cancer Drug Targets"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2018\/e557s","article-title":"Radiotherapy and immune response: the systemic effects of a local treatment","volume":"73","author":"de Andrade Carvalho","year":"2018","journal-title":"Clinics"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33424","article-title":"Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety","volume":"127","author":"Williamson","year":"2021","journal-title":"Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt-2017-0082","article-title":"Radiation therapy and immunotherapy: what is the optimal timing or sequencing","volume":"10","author":"Aliru","year":"2018","journal-title":"Immunotherapy"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101366","article-title":"Radiotherapy: Brightness and darkness in the era of immunotherapy","volume":"19","author":"Zhai","year":"2022","journal-title":"Transl Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i20.2416","article-title":"Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma","volume":"25","author":"Choi","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijrobp.2020.05.011","article-title":"Optimizing radiation therapy to boost systemic immune responses in breast cancer: a critical review for breast radiation oncologists","volume":"108","author":"Ho","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100867","article-title":"Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization","volume":"36","author":"Rajeev-Kumar","year":"2023","journal-title":"Neoplasia N Y N"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-17-0743","article-title":"Harnessing and optimizing the interplay between immunotherapy and radiotherapy to improve survival outcomes","volume":"16","author":"Mujoo","year":"2018","journal-title":"Mol Cancer Res MCR"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157164","article-title":"Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy","volume":"11","author":"Young","year":"2016","journal-title":"PloS One"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12010007","article-title":"Therapeutic in situ cancer vaccine using pulsed stereotactic body radiotherapy-a translational model","volume":"12","author":"Swamy","year":"2023","journal-title":"Vaccines"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1002957","article-title":"Vascular normalization and immunotherapy: Spawning a virtuous cycle","volume":"12","author":"Swamy","year":"2022","journal-title":"Front Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.729250","article-title":"Stereotactic body radiotherapy immunological planning-a review with a proposed theoretical model","volume":"12","author":"Swamy","year":"2022","journal-title":"Front Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010052","article-title":"Immune checkpoint inhibitors in mismatch repair proficient\/microsatellite stable metastatic colorectal cancer patients: Insights from the AtezoTRIBE and MAYA trials","volume":"14","author":"Germani","year":"2021","journal-title":"Cancers"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004487","article-title":"Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation","volume":"10","author":"Wen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.963964","article-title":"Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Genet"},{"key":"B137","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","article-title":"POLE\/POLD1 mutation and tumor immunotherapy","volume":"41","author":"Ma","year":"2022","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.5603\/njo.a2022.0024","article-title":"Immunological aspects of heat shock protein functions and their significance in the development of cancer vaccines","volume":"7","author":"Boliukh","year":"2022","journal-title":"Biul Pol Tow Onkol Nowotw"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3267207","article-title":"Heat shock proteins in cancer immunotherapy","volume":"2019","author":"Das","year":"2019","journal-title":"J Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2023.10.005","article-title":"Heat shock proteins in cancer - known but always being rediscovered: their perspectives in cancer immunotherapy","volume":"68","author":"Mazurakova","year":"2023","journal-title":"Adv Med Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113934","article-title":"Advances in DNA repair\u2014emerging players in the arena of eukaryotic DNA repair","volume":"21","author":"Kciuk","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B142","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1038\/ncomms6513","article-title":"HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase \u03b2","volume":"5","author":"Fang","year":"2014","journal-title":"Nat Commun"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2014.02.002","article-title":"Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells","volume":"322","author":"Tung","year":"2014","journal-title":"Exp Cell Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203617109","article-title":"Heat shock protein 90\u03b1 (HSP90\u03b1), a substrate and chaperone of DNA-PK necessary for the apoptotic response","volume":"109","author":"Solier","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.10.094","article-title":"Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin","volume":"351","author":"Noguchi","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-2181","article-title":"Inhibition of hsp90 compromises the DNA damage response to radiation","volume":"66","author":"Dote","year":"2006","journal-title":"Cancer Res"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-11-0094","article-title":"Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage","volume":"10","author":"Ha","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.05.028","article-title":"Inhibition of Hsp27 radiosensitizes head-and-neck cancer by modulating deoxyribonucleic acid repair","volume":"87","author":"Guttmann","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-1929","article-title":"TAS-116 (Pimitespib), an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: an open-label, dose-finding, and expansion phase Ib trial (EPOC1704)","volume":"27","author":"Kawazoe","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31214","article-title":"The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine","volume":"124","author":"Riley","year":"2018","journal-title":"Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3390\/life12020229","article-title":"Landscape of immunotherapy options for colorectal cancer: Current knowledge and future perspectives beyond immune checkpoint blockade","volume":"12","author":"Gorzo","year":"2022","journal-title":"Life"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.01.015","article-title":"Gut microbiome and cancer immunotherapy","volume":"447","author":"Li","year":"2019","journal-title":"Cancer Lett"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v14.i9.1665","article-title":"Implication of gut microbiome in immunotherapy for colorectal cancer","volume":"14","author":"Koustas","year":"2022","journal-title":"World J Gastrointest Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128774","article-title":"Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13578-023-01135-y","article-title":"The impact of the gut microbiome on tumor immunotherapy: From mechanism to application strategies","volume":"13","author":"Guo","year":"2023","journal-title":"Cell Biosci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1918429\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:14:13Z","timestamp":1785924853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1918429\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":155,"alternative-id":["10.3389\/fimmu.2026.1918429"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1918429","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1918429"}}